[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glaucoma-following-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glaucoma-following-surgery":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100453166",false,"NCT05180994","Topical Infliximab in Eyes With Penetrating Keratoplasty","Inclusion Criteria:\n\n* Age between 18 and 80 years;\n* First corneal transplant surgery;\n* Capable of providing informed consent;\n* Capable of administering eye medication or access to a caregiver able and willing to administer the eye medication for the patient.\n\nExclusion Criteria:\n\n* Active ocular infection;\n* Past corneal transplant (any technique);\n* Advanced glaucoma or macular disease;\n* Active or latent systemic infection (tuberculosis, histoplasmosis, coccidioidomycosis, cytomegalovirus, pneumocystis, aspergillosis or hepatitis B);\n* Malignancy diagnosed in the past 5 years (any kind);\n* Demyelinating disease;\n* History or current diabetes mellitus (controlled or uncontrolled) or heart failure (New York Heart Association class III or IV);\n* Pregnancy or breastfeeding;\n* Allergy to infliximab or to a compound of its topical formulation;\n* Significant anomaly of complete blood count or hepatic enzymes;\n* Current or anterior use of anti-TNF-α medication or other anti-inflammatory biologics.","ALL","18 Years","80 Years",{"count":18,"type":19},50,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","Penetrating keratoplasty is a cornea surgery involving several inflammatory complications, of which the most important is glaucoma. Researchers wish to determine whether it is safe to administer infliximab (an anti-inflammatory drug) eye drops after surgery, and whether this eye drop could prevent the occurrence of glaucoma.",[26],"Glaucoma Following Surgery","RECRUITING","2026-04-23",{"date":30,"type":31},"2026-04-27","ACTUAL",{"date":33,"type":31},"2022-05-01",{"date":35,"type":19},"2028-03-01",{"name":37,"class":38},"Centre hospitalier de l'Université de Montréal (CHUM)","OTHER",""]